On-demand plerixafor added to high-dose cyclophosphamide and pegylated recombinant human granulocyte colony-stimulating factor in the mobilization of patients with multiple myeloma: a treatment with high effectiveness, convenient, and affordable cost

ObjectiveThe combination of high-dose cyclophosphamide (HD-Cy) (3g/m2) plus granulocyte colony-stimulating factor (G-CSF) and on-demand plerixafor (PXF) has been considered an effective mobilization regimen of patients with multiple myeloma(MM). However, the daily multi-injection regimen of G-CSF po...

Full description

Bibliographic Details
Published in:	Frontiers in Oncology
Main Authors:	Li-qiong Hou, Jun-Ru Liu, Jing-Li Gu, Mei-Lan Chen, Li-Fen Kuang, Bei-Hui Huang, Wai-yi Zou, Juan Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Subjects:	pegylated granulocyte colony-stimulating factor cyclophosphamide plerixafor stem cell mobilization multiple myeloma
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1306367/full

Similar Items

Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma
by: Flavia Bigi, et al.
Published: (2024-04-01)

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
by: Zoe van de Wyngaert, et al.
Published: (2023-02-01)

Moving Beyond G‐CSF Mobilization—Learning From a 15‐Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma
by: Sumeet Mirgh, et al.
Published: (2025-07-01)

The efficacy and safety of plerixafor in hematopoietic stem cell mobilization in patients with Non-Hodgkin lymphoma, multiple myeloma, and Hodgkin lymphoma who failed mobilization with granulocyte-colony-stimulating factor alone: A single-center experience
by: Girish Badarkhe, et al.
Published: (2020-01-01)

Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
by: Rishi Agarwal, et al.
Published: (2012-12-01)

Use of Plerixafor to Mobilize a Healthy Donor Infected with Influenza A
by: Mahmut Yeral, et al.
Published: (2018-05-01)

pH-Responsive PEGylated Niosomal Nanoparticles as an Active-Targeting Cyclophosphamide Delivery System for Gastric Cancer Therapy
by: Farnaz Khodabakhsh, et al.
Published: (2022-08-01)

Preemptive and upfront plerixafor: Safe and effective strategy for patients undergoing autologous stem cell transplant and at high risk for mobilization failure
by: Vipul Sheth, et al.
Published: (2020-01-01)

Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2023 edition)
by: Jun Wang, et al.
Published: (2023-09-01)

Plerixafor in Patients with Decreased Mobilizing Ability of Autologous Hematopoietic Stem Cells
by: MA Kucher, et al.
Published: (2016-04-01)

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
by: Yan Wang, et al.
Published: (2025-02-01)

G-CSF + plerixafor versus G-CSF alone mobilized hematopoietic stem cells in patients with multiple myeloma and lymphoma: a systematic review and meta-analysis
by: Yuyao Li, et al.
Published: (2024-12-01)

Plerixafor use in autologous hematopoietic stem cell mobilization: Experience from a single center in Southern India
by: Soumya Das, et al.
Published: (2022-01-01)

Prolonged infusion time of cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) as a mobilization regimen may improve mobilization efficiency in newly diagnosed multiple myeloma patients: a single center experience
by: Yanjuan Li, et al.
Published: (2023-12-01)

Pegylated liposomal doxorubicin combined with cyclophosphamide and vincristine in pediatric patients with relapsed/refractory solid tumor: a single-arm, open-label, phase I studyResearch in context
by: Suying Lu, et al.
Published: (2024-07-01)

Effects of pegylated recombinant human granulocyte colony-stimulating factor on lymphocytes and white blood cells of patients with malignant tumor
by: Zhao Tong, et al.
Published: (2023-04-01)

A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer
by: Dongling Zou, et al.
Published: (2021-06-01)

Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group
by: Reza Safaee, et al.
Published: (2012-07-01)

Outcomes of upfront plerixafor use for mobilization in germ cell tumor patients
by: Jaimie Cohen, et al.
Published: (2024-11-01)

Intravitreal Injection of Long-Acting Pegylated Granulocyte Colony-Stimulating Factor Provides Neuroprotective Effects via Antioxidant Response in a Rat Model of Traumatic Optic Neuropathy
by: Chin-Te Huang, et al.
Published: (2021-12-01)

A novel PEGylated form of granulocyte colony-stimulating factor, mecapegfilgrastim, for peripheral blood stem cell mobilization in patients with hematologic malignancies
by: Jingjing Wen, et al.
Published: (2023-07-01)

Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment
by: Min Ji Jeon, et al.
Published: (2024-11-01)

Use of plerixafor for hematopoietic stem cells mobilization in allograft donors
by: D. N. Balashov, et al.
Published: (2015-01-01)

An evidence-based and risk-adapted GSF versus GSF plus plerixafor mobilization strategy to obtain a sufficient CD34+ cell yield in the harvest for autologous stem cell transplants
by: Milena Todorović Balint, et al.
Published: (2024-01-01)

CHARACTERISTICS OF NEUTROPHIL CHEMILUMINESCENCE IN PATIENTS WITH TYPE G MULTIPLE MYELOMA AT DIFFERENT STAGES OF THE DISEASE
by: O. V. Smirnova, et al.
Published: (2016-01-01)

Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)
by: Motoko Tachihara, MD, PhD, et al.
Published: (2023-10-01)

The Value of Immature Granulocyte and Immature Granulocyte/Total Granulocyte Ratio in Predicting the Need for Surgical Treatment in Patients Diagnosed with Intestinal Ileus in the Emergency Department
by: Yunsur Çevik, et al.
Published: (2023-08-01)

Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography revealed the course of granulocyte-colony stimulating factor-associated aortitis: A case report
by: Yoichiro Hijikata, MD, et al.
Published: (2024-09-01)

Rapid high‐dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma
by: Marcus Marable, et al.
Published: (2024-12-01)

Potential applications of PEGylated green gold nanoparticles in cyclophosphamide-induced cystitis
by: Bushra Shal, et al.
Published: (2022-12-01)

Evaluation of granulocyte colony-stimulating factor effect on the expression of inhibitory receptors by T cells in multiple myeloma
by: E. V. Batorov, et al.
Published: (2024-07-01)

Comparison of the effects of pegylated granulocyte-colony stimulating factor and granulocyte-colony stimulating factor on cytopenia induced by dose-dense chemotherapy in breast cancer patients
by: Farzaneh Ashrafi, et al.
Published: (2018-01-01)

Carbohydrate PEGylation, an approach to improve pharmacological potency
by: M. Eugenia Giorgi, et al.
Published: (2014-06-01)

Febrile neutropenia incidence and the variable toxicity profile between brand and generic docetaxel in the adjuvant treatment of breast cancer with docetaxel and cyclophosphamide regimen
by: Flávia Viécili Tarcha, et al.
Published: (2023-12-01)

Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report
by: Mazen Kreidy, et al.
Published: (2020-01-01)

Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients
by: Cristina Potre, et al.
Published: (2022-11-01)

Bilateral exudative retinal detachment with subretinal light-chain protein in a patient with multiple myeloma -case report-
by: Arved Rikus Gruben, et al.
Published: (2024-10-01)

Pegylation, as method of production prolonged forms of biopharmaceutical drugs (pegylated granulocyte colony-stimulating factor as case of study)
by: I. А. Puchkov, et al.
Published: (2014-04-01)

Successful Stem Cell Mobilization and CD34+ Cell Collection in a Poor Mobilizer: A Case Report Utilizing a Combination of Recombinant Growth Colony Stimulating Factor, Recombinant Human Growth Factor, and Plerixafor
by: Maliheh Kazemi Najafabadi, et al.
Published: (2024-04-01)

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
by: Ka‐Won Kang, et al.
Published: (2020-09-01)